Effect of aripiprazole on prolactinemia induced by antidepressants in patients with depression / 中国神经精神疾病杂志

ABSTRACT

Objective To investigate the effect and safety of different doses of aripiprazole on hyperprolactinemia (HPL) induced by antidepressants such as Selective Serotonin Reuptake Inhibitor (SSRIs). Methods One hundred and thirty-five depressive patients with SSRIs antidepressant-induced hyperprolactinemia were randomly divided into three groups and 95 cases who finished the study were included in the study. Thirty-three cases in group 1 were treated with aripiprazole 5 mg/d, thirty-two cases in group 2 were treated with aripiprazole 10 mg/d and thirty cases in control group were treated with SSRI alone. All three groups also received cognitive behavioral therapy in addition to antidepressants for 12 weeks. Serum prolactin levels were examined before admission and 4, 8 and 12 weeks after treatment. Hamilton Depression Scale (HAMD), Global Assessment Function (GAF) and Treatment Emergent Symptom Scale (TESS) were used to evaluate the efficacy and adverse reactions. Results At the end of the 4, 8 and 12 weeks, the serum prolactin level in group 1 and group 2 were significantly lower than those in control group (P<0.05). At the end of 8 and 12 weeks, the HAMD scores of group 1 and 2 group were significantly lower than those of the control group (P<0.01). At the end of 4, 8, and 12 weeks, the GAF scores of group 1 and 2 group were significantly higher than those of the control group (P< 0.01). However, there were no significant differences in prolactin levels, HAMD and GAF scores between group 1 and group 2 (P>0.05). There was no significant difference in the rate of adverse reaction among the three groups (P>0.05). Conclusion Aripiprazole can reduce the hyperprolactinemia caused by SSRIs antidepressants and synergistically enhance efficacy of antidepressant.